Skip to main content
Premium Trial:

Request an Annual Quote

Stevan Jovanovich Named President and CEO of Microchip Biotechnologies, MDS Appoints Nils Hoem as Director of Pharmacokinetics/Pharmacodynamics in Europe, Others

Stevan Jovanovich, former vice president of global research at Amersham Biosciences, has been named president and CEO of Microchip Biotechnologies of Fremont, Calif., a startup that last month received a $6.1 million grant from NHGRI to develop a DNA sequencing technology.

MDS Pharma has appointed Nils Hoem as director of pharmacokinetics/pharmacodynamics in Europe, the company said last week. Hoem will be responsible for managing a team of approximately 15 scientists located in MDS' European clinical pharmacology units. Prior to joining MDS, Hoem ran his own business, Hoem Pharma Consulting. He was also employed by Smerud Medical Research Group and the Universityof Oslo. He holds a PhD in clinical pharmacokinetics and pharmacodynamics from the Universityof Oslo.

Millipore announced last week that its new president and CEO, Martin Madaus, will start on Jan. 1, 2005. As previously announced, he is assuming the roles of president and CEO from Francis Lunger, who will remain as chairman of the board until March 1, 2005.

Metaphore Pharmaceuticals of Fort Lee, NJ, has elected Harold Ingalls to its board of directors. Ingalls is the CFO of Serologicals.

BioCrossroads, the Indiana's public-private life sciences initiative, has named David Johnson as its CEO, replacing Charles Schalliol, who is stepping down. Johnson is a partner in the Indianapolislaw firm of Baker & Daniels. AS CEO, he will continue an effort to create the Indiana Seed Fund, an early stage venture capital fund aimed at promising Indianalife sciences opportunities. Johnson currently serves on the BioCrossroads board of directors.

Ruedi Aebersold, professor of systems biology at the Instituteof Biology, Swiss Federal Institute of Technology, in Zurich, has joined the scientific advisory board of biomedical software firm Insilicos.

J. Scott Tarrant has joined contract research organization Xceleron as vice president of business development for North America. Prior to joining the UK-based firm, Tarrant was responsible for leading a sales organization for genomics and preclinical CRO services at Gene Logic.

Sirna Therapeutics announced this week a number of new appointment in conjunction with its establishment of a dermatology division. The company said that Angela Christiano, an associate professor at ColumbiaUniversityand co-founder of recent Sirna acquisition Skinetics Biosciences, will act as a consultant to Sirna's dermatology division. Sirna also said that Joseph Carroll, formerly a senior scientist at Millennium Pharmaceuticals, has joined the dermatology division. Colin Jahoda, of Skinetics, will also serve as a consultant to the new division.


In addition, Sirna announced the establishment of a scientific advisory board for Sirna Dermatology. The new members of the SAB include Paul Khavari, a professor at Stanford University School of Medicine. Khavari holds a PhD from Stanford and an MD from YaleUniversity, said Sirna. Also joining the SAB are James Krueger, a professor at Rockefeller University who holds a PhD from Rockefeller and an MD from Cornell University Medical College; Thomas Kupper, a professor at Harvard Medical School with an MD from Yale University's School of Medicine; Elise Olsen, a professor at Duke University Medical Center; and Fiona Watt, a researcher at Cancer Research UK.

Marc Rivière has been appointed executive vice president of clinical development for Caprion Pharmaceuticals. Prior to joining Caprion, he served as chief medical officer for Bioniche Life Sciences.

Michael Spicer has resigned his position as senior vice president of finance and CFO of Orchid Biosciences to accept a position at a publicly traded biopharmaceutical firm, Orchid announced. Spicer's resignation is effective Dec. 31. He joined the firm through its 2001 acquisition of Lifecodes, and has served as CFO since July 2003.

Thomas Lawlor has joined SeraCare Life Sciences as global chief operating officer. He joins the firm from Haemonetics, where he most recently served as vice president of USblood bank and field services operations.

In connection with its integration with Inveresk Research Group, Charles River Laboratories has promoted Nancy Gillet to the post of senior vice president and president of global preclinical services for. Gillet succeeds Michael Ankcorn, who is retiring from the firm effective Dec. 31. She previously served as corporate vice president and president of US preclinical services.

In addition, Charles Riverannounced that Glenn Kerkhof was named interim president of global clinical services, succeeding Alistair McEwan, who left the company last week. Paul Oskar was promoted to general manager and president of US preclinical services from his previous position as general manager, DDS Worcester division. Christopher Perkin, the firm's current chief operating officer of CTBR, was named general manager and president of Canadian preclinical services.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.